Himension Capital Singapore PTE. LTD. Sells 149,022 Shares of Intellia Therapeutics, Inc. $NTLA

Himension Capital Singapore PTE. LTD. decreased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 25.8% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 429,540 shares of the company’s stock after selling 149,022 shares during the period. Himension Capital Singapore PTE. LTD.’s holdings in Intellia Therapeutics were worth $5,507,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Wesbanco Bank Inc. bought a new position in shares of Intellia Therapeutics during the fourth quarter valued at $575,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Intellia Therapeutics in the 1st quarter valued at $1,809,000. Canal Insurance CO bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $899,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $318,000. Finally, GSA Capital Partners LLP increased its position in shares of Intellia Therapeutics by 210.4% during the 4th quarter. GSA Capital Partners LLP now owns 233,080 shares of the company’s stock worth $2,095,000 after purchasing an additional 157,989 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NTLA. Citizens Jmp reissued a “market outperform” rating and set a $30.00 price target on shares of Intellia Therapeutics in a report on Monday, June 15th. The Goldman Sachs Group upped their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, April 28th. Chardan Capital raised their price objective on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. New Street Research set a $25.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 15th. Finally, Robert W. Baird boosted their target price on Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $20.19.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $11.47 on Wednesday. The firm has a market cap of $1.60 billion, a P/E ratio of -3.24 and a beta of 1.77. The firm has a 50 day simple moving average of $14.17 and a 200 day simple moving average of $13.46. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The firm had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter in the previous year, the company posted ($1.10) EPS. On average, sell-side analysts expect that Intellia Therapeutics, Inc. will post -3.18 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 2,641 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the transaction, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. The trade was a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 3.50% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.